IP Library › Granted Patent US 11,767,366
Granted Patent B1
US 11,767,366 · App. 18/066,420 · Granted Sep 26, 2023

Pseudotyped viral particles, compositions comprising the same, and uses thereof

Inventors: Ronnie M. Russell (Philadelphia, PA); Philip R. Johnson (Philadelphia, PA)
Assignee: INTERIUS BIOTHERAPEUTICS, INC.
C07K16/2896C12N15/113C12N15/86C12N2740/15043
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,767,366
App. No.
18/066,420
Granted
Sep 26, 2023
Kind
B1
Abstract

Provided for herein are mutant VSV-G polypeptides, compositions comprising the same, and methods of using the same. Also provided for herein are polypeptides and compositions that bind to CD7 and uses thereof. Also provided for herein are polypeptides and compositions that bind to CD8 and uses thereof.

Claims (30)

1. A polypeptide comprising an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 2 and a I182E mutation as compared to SEQ ID NO: 2.

2. A polypeptide comprising an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 2 and a I182D mutation as compared to SEQ ID NO: 2.

3. The polypeptide of claim 1 , wherein the polypeptide further comprises a mutation at position 214, a mutation at position 352, or a mutation at both position 214 and position 352 as compared to SEQ ID NO: 2.

4. The polypeptide of claim 1 , wherein the polypeptide further comprises a T214N mutation, a T352A mutation, or a combination thereof, as compared to SEQ ID NO: 2.

5. The polypeptide of claim 1 , wherein the polypeptide further comprises a T214N mutation and a T352A mutation as compared to SEQ ID NO: 2.

6. The polypeptide of claim 2 , wherein the polypeptide further comprises a mutation at position 214, a mutation at position 352, or a mutation at both position 214 and 352, as compared to SEQ ID NO: 2.

7. The polypeptide of claim 2 , wherein the polypeptide further comprises a T214N mutation, a T352A mutation, or a combination thereof, as compared to SEQ ID NO: 2.

8. The polypeptide of claim 2 , wherein the polypeptide further comprises a T214N mutation and a T352A mutation as compared to SEQ ID NO: 2.

9. The polypeptide of claim 1 , wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 23.

10. A nucleic acid molecule encoding the polypeptide of claim 1 .

11. A vector comprising the nucleic acid molecule of claim 10 .

12. A cell comprising the nucleic acid molecule of claim 10 .

13. A viral particle comprising the polypeptide of claim 1 .

14. The viral particle of claim 13 , wherein the viral particle is a lentivirus comprising the polypeptide.

15. The viral particle of claim 13 , wherein the viral particle further comprises a heterologous nucleic acid molecule encoding a heterologous molecule of interest.

16. The viral particle of claim 15 , wherein the heterologous molecule of interest is an siRNA, an shRNA, a non-coding RNA, a polypeptide, a viral payload, a viral genome, or a combination thereof.

17. The viral particle of claim 15 , wherein the heterologous molecule of interest is a chimeric antigen receptor (“CAR”).

18. The polypeptide of claim 1 , wherein the polypeptide, comprises an amino acid sequence that is at least 96% identical to the amino acid sequence of SEQ ID NO: 2.

19. The polypeptide of claim 1 , wherein the polypeptide comprises an amino acid sequence that is at least 97% identical to the amino acid sequence of SEQ ID NO: 2.

20. The polypeptide of claim 1 , wherein the polypeptide comprises an amino acid sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO: 2.

21. The polypeptide of claim 1 , wherein the polypeptide comprises an amino acid sequence that is at least 99% identical to the amino acid sequence of SEQ ID NO: 2.

22. The polypeptide of claim 2 , wherein the polypeptide comprises an amino acid sequence that is at least 96% identical to the amino acid sequence of SEQ ID NO: 2.

23. The polypeptide of claim 2 , wherein the polypeptide comprises an amino acid sequence that is at least 97% identical to the amino acid sequence of SEQ ID NO: 2.

24. The polypeptide of claim 2 , wherein the polypeptide comprises an amino acid sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO: 2.

25. The polypeptide of claim 2 , wherein the polypeptide comprises an amino acid sequence that is at least 99% identical to the amino acid sequence of SEQ ID NO: 2.

26. The polypeptide of claim 2 , wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 22.

27. A viral particle comprising the polypeptide of claim 9 .

28. The viral particle of claim 27 , wherein the viral particle further comprises a nucleic acid molecule encoding a chimeric antigen receptor.

29. A viral particle comprising the polypeptide of claim 26 .

30. The viral particle of claim 29 , wherein the viral particle further comprises a nucleic acid molecule encoding a chimeric antigen receptor.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 31, 2023
From: RUSSELL, RONNIE M.; JOHNSON, PHILIP R.; ANDORKO, JAMES I.; SACHDEVA, MOHIT; SCHNEPP, BRUCE; MARINELLI, MICHAEL; FOSS, JEFFERY; BORAL, DEBASISH
To: INTERIUS BIOTHERAPEUTICS, INC.
Reel/Frame 065409/0318 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 23, 2023
From: RUSSELL, RONNIE M.; JOHNSON, PHILIP R.; ANDORKO, JAMES I.; SACHDEVA, MOHIT; SCHNEPP, BRUCE; MARINELLI, MICHAEL; FOSS, JEFFREY; BORAL, DEBASISH
To: INTERIUS BIOTHERAPEUTICS, INC.
Reel/Frame 062456/0128 →
Continuity (4)
Provisional Application 63267039 · Jan 21, 2022
Provisional Application 63266044 · Dec 27, 2021
Provisional Application 63289977 · Dec 15, 2021
Provisional Application 63289888 · Dec 15, 2021
Cited By (7)
US 12,252,512 US 12,269,882 US 12,312,593 US 12,398,377 US 12,403,194 US 12,435,140 US 12,440,564